Recent advances in blood cancer treatments are offering patients safer options and longer-lasting remissions. Studies highlight the potential of CAR T-cell therapy in multiple myeloma, a gentler ...
Johnson & Johnson announced that it entered into a definitive agreement to acquire Atraverse Medical. Regeneron struck a drug pricing deal with the Trump administration to reduce prices on drugs for ...
Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...
Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood cancer treatment ...
US pharma giant Pfizer has announced positive topline results from the Phase III MagnetisMM-5 study of Elrexfio (elranatamab) ...
Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...
Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Thursday, April 30, 2 ...
Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.
Diagnosed with both AIDS and cancer, a writer finds solace in the Cape May surf and the profound gift of a friend truly engaging with his life’s work.
Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, ...
A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results